Bristol-Myers Squibb Company (BMY)
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
Bristol Myers' heart disease drug fails to meet main goals in late-stage study
Bristol Myers Squibb said on Monday its experimental drug to treat a type of heart disease did not meet the main goals in a late-stage study.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $53.78, denoting a +1.34% change from the preceding trading day.
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.
Bristol Myers wins dismissal of lawsuit alleging Pomalyst monopoly
Bristol Myers Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing sham patent lawsuits to maintain an illegal monopoly on its blockbuster blood cancer drug Pomalyst, keeping cheaper generic versions off the market.
Hedge Funds Are Dumping Tech Stocks: Grab These 4 Safety Net High-Yield Dividend Giants Now
Hedge funds are rapidly reducing their exposure to global information technology stocks, with the latest selloff marking the fastest decline in six months.
